Thrive Earlier Detection→Exact Sciences
Acquisition · Cash + Stock · EXAS · announced Oct 27, 2020
Announced
Oct 27, 2020
Closed
Jan 5, 2021
Economics
Cash + Stock()
Pre-deal · pre-deal mark: 2020, year precision · rounding grid ±$100M · Exact Sciences press release — Thrive Earlier Detection acquisition, 2021
~$2.15B cash + stock
Target
Thrive Earlier Detection
Diagnostics · Diagnostic / genomic
HQ Cambridge, MA · Founded 2019
Multi-cancer blood test (CancerSEEK) using cfDNA and protein biomarkers to detect multiple cancer types including breast and ovarian
- PR Newswire — Exact Sciences/Thrive announcement (Oct 27, 2020)
- PR Newswire — Exact Sciences completion (Jan 5, 2021)
- Milwaukee Business Journal (Jan 5, 2021)
Acquirer
Exact Sciences (EXAS)
Precision Medicine
HQ Madison, WI
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
CancerSEEK multi-cancer blood test detects 10+ cancer types including breast and ovarian via cfDNA and protein biomarkers — combined with Cologuard and Oncotype DX to create most comprehensive cancer screening portfolio
Evidence ladder
Secondary (press / IR)
PR Newswire — Exact Sciences announcement (Oct 27, 2020)
Tertiary (trade / analyst)
completion (Jan 5, 2021)
Limitations
- Citations are press/IR only — two wires of the same announcement are not dual-source. Add a primary filing.
- ~$2.15B cash + stock
- Pre-deal valuation sourced from: Exact Sciences press release — Thrive Earlier Detection acquisition, 2021. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Diagnostics
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer.
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Target | Acquirer | Announced | Value | Vs this deal |
|---|---|---|---|---|
| Counsyl | Myriad Genetics | May 28, 2018 | ||
| nVision Medical | Boston Scientific | Apr 16, 2018 | ||
| PreventionGenetics | Exact Sciences | Jan 9, 2022 | ||
| Gateway Genomics | Myriad Genetics | Nov 1, 2022 |
Other verified deals by Exact Sciences
Acquirer program history not already listed as a valuation peer or adjacency row.
| Target | Acquirer | Announced | Value | Sector |
|---|---|---|---|---|
| Genomic Health | Exact Sciences | Jul 29, 2019 | Precision Medicine |
Patient empowerment context
Empowerment context — Thrive Earlier Detection
Curated survey mappingHLTH/Outcomes4Me 2022 surveyed breast cancer patients (n=1,828). Breast cancer care continuum (HLTH 2022). Rows below are analyst-curated mappings to cited survey items — not live patient outcomes for this target.
- Presented with clinical trial as treatment option1 in 5cited HLTH 2022
Other curated mappings on these gaps: Genomic Health, Foundation Medicine, Flatiron Health, GRAIL
Full cited gap matrix →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.